CNN reported on Friday that the US Food and Drug Administration authorised a new test that diagnoses both influenza and for COVID-19, CNN reported on Friday.
The test, designed by the US Centers for Disease Control and Prevention (CDC), is the first dual test to get emergency use authorisation from the FDA.
FDA Commissioner Stephen Hahn was quoted as saying in a statement:
"With the authorisation of these tests, the FDA is helping address concerns in anticipation of this upcoming flu season during the COVID-19 pandemic, which might be especially worrying for some Americans."
"With just one swab or sample, combination tests can be used to get answers to Americans faster. This efficiency can go a long way to providing timely information for those sick with an unknown respiratory ailment," Hahn added.
AstraZeneca's Trixeo Aerosphere approved in EU for asthma maintenance treatment
Insmed's ARIKAYCE sNDA granted priority review by FDA
Precigen announces FDA platform technology designation for AdenoVerse
Kelun-Biotech publishes phase III data for trastuzumab botidotin in HER2-positive breast cancer
GSK reports positive Jideytro data supporting potential first-line lung cancer use
Akeso presents positive results from registrational Phase III study of ivonescimab
Insilico Medicine doses first patient in Phase III trial of rentosertib
Altesa BioSciences presents positive vapendavir clinical data at ERS International Congress 2026
Akeso's ivonescimab meets overall survival endpoint in interim analysis of Phase III HARMONi-2 study
AstraZeneca completes global licence agreement for Zegfrovy
Kazia Therapeutics reports 100% clinical benefit rate in initial paxalisib breast cancer trial
Oxcia receives EMA orphan designation for OXC-201 in idiopathic pulmonary fibrosis
Cizzle Bio presents CIZ1B biomarker blood test for lung cancer at Next Generation Dx Summit
Maverix Medical's Narwhal Cryo System receives FDA 510(k) clearance